Heart failure is a clinical syndrome caused by structural and / or cardiac functional disorders. It is the final phase of all heart disease. This situation will lead to decreased functional capacity and quality of life of patients. Because of that, many studies was conducted on cardiac biomarkers such as Suppression of tumorigenicity-2, Galectin-3, high sensitivity troponin to assess prognostic and risk stratification of heart failure. Suppression of tumorigenicity-2 (ST2) is one of the biomarkers depicting fibrosis and remodeling that occurs in the heart, and can be used to predict cardiovascular events, rehospitalization, and death. It may also be used to assess the prognostics of heart failure and therapeutic response. Cardiac remodeling and fibrosis that occur in heart failure decreases functional capacity in patients with heart failure. The most convenient functional capacity assessment is a six-minute walking test (6MWT). There are several other walking tests but two-minute walkingÂ test is an alternative that is often used usually in elderly patients, patient with motoric disorder and patients who have difficulty walking for long periods of time. This condition of decrease functional capacity will affect the quality of life of patients with heart failure. There are various questionnaires to assess quality of life, from general questionnaires to assessing the quality of the life to the specific questionnaire of patients with heart failure. Until now, the Minnesota Living with Heart Failure Questionnaire is the most frequently used questionnaire. This is because it covers the physical, emotional and social aspects and has a correlation to the functional capacity of patients with heart failure.
Rampengan, S. H., Pangemanan, J. A., Gunadi, J., & Lampus, N. (2017). The role of suppression of tumorigenicity-2 on the quality of life of patients with heart failure. Bali Medical Journal, 6(3). https://doi.org/10.15562/bmj.v6i3.993